Article
Endocrinology & Metabolism
Mirela-Diana Ilie, Antoine Tabarin, Alexandre Vasiljevic, Jean-Francois Bonneville, Lucile Moreau-Grange, Franck Schillo, Brigitte Delemer, Anne Barlier, Dominique Figarella-Branger, Segolene Bisot-Locard, Alexandre Santos, Philippe Chanson, Gerald Raverot
Summary: This study aimed to explore the factors related to SRLs in the treatment of acromegaly and confirmed that SST2A and adenoma granularity are good predictors of response to octreotide. In addition, the optimization of MRI sequences is important for using T2WSI as a predictor of treatment response.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonio Bianchi, Antonella Giampietro, Alfredo Pontecorvi, Gerald Raverot, Laura De Marinis
Summary: This review provides an overview of the second-line therapies for acromegaly, summarizing the evidence on clinical, molecular, and morphological aspects that can predict the response to these treatments and advocating for a patient-tailored therapeutic approach in clinical practice.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Medicine, General & Internal
Alexandru Dan Popescu, Mara Carsote, Ana Valea, Andreea Gabriela Nicola, Ionela Teodora Dascalu, Tiberiu Tirca, Jaqueline Abdul-Razzak, Mihaela Jana Tuculina
Summary: Acromegaly-related sub/infertility is associated with suboptimal disease control, hyperprolactinemia, hypogonadotropic hypogonadism, and glucose profile anomalies. This review explores the impact of acromegaly on pregnancy outcomes and discusses management strategies. The level of disease control, family history of diabetes, and body mass index are important predictors of maternal complications. Pharmacotherapy has been shown to be safe and effective in improving pregnancy outcomes.
Review
Medicine, Research & Experimental
Jacobo Kerbel, Amayrani Cano-Zaragoza, Rodrigo Espinosa-Dorado, Keren-Enid Garcia de la Torre, Moises Mercado
Summary: National registries are valuable tools to investigate rare conditions like acromegaly, providing insights into epidemiology, clinical presentation, diagnosis, treatment outcomes, and mortality. While single-center studies are more homogeneous, they are often limited by small sample sizes and lack statistical power.
ARCHIVES OF MEDICAL RESEARCH
(2023)
Article
Endocrinology & Metabolism
Luigi Maione, Cristina Albrici, Solange Grunenwald, Celine Mouly, Vincenzo Cimino, Anne-Lise Lecoq, Jean Claude Souberbielle, Philippe Caron, Philippe Chanson
Summary: This study compared the serum IGF-I dynamics and variability in patients treated with SRLs, surgically cured patients, and healthy controls. The results showed that IGF-I decreased significantly at Day 7 and Day 14 after injection in SRL-treated patients, but remained stable in cured patients and healthy controls. In addition, SRL-treated patients had higher IGF-I variability, especially in nonoptimally controlled patients. The measurement at the farthest distance from SRL injection was the best predictor of optimal disease control.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Review
Endocrinology & Metabolism
Monica R. Gadelha, Ana Carolina Gadelha, Leandro Kasuki
Summary: The treatment of acromegaly has advanced significantly in recent decades, but there are still patients who do not respond to current treatments, highlighting the need for improved treatment burden. Fortunately, there are new treatments in development that may enhance treatment efficacy and convenience.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Artak Labadzhyan, L. B. Nachtigall, M. Fleseriu, M. B. Gordon, M. Molitch, L. Kennedy, S. L. Samson, Y. Greenman, N. Biermasz, M. Bolanowski, A. Haviv, W. Ludlam, G. Patou, C. J. Strasburger
Summary: Results from trials investigating oral octreotide capsules as an alternative treatment for acromegaly showed consistent biochemical response, durability of response, and patient preference for oral treatment, despite differences in trial design.
Article
Endocrinology & Metabolism
Sabrina Chiloiro, Antonella Giampietro, Federica Mirra, Federico Donfrancesco, Tommaso Tartaglione, Pier Paolo Mattogno, Flavia Angelini, Lauretti Liverana, Marco Gessi, Anile Carmelo, Guido Rindi, Andrea Giustina, Maria Fleseriu, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianchi
Summary: The study investigated predictors of response to Pegvisomant and Pasireotide LAR in acromegaly patients, finding that factors such as tumor extension, Ki67-Li levels, and IGF-I levels may impact treatment efficacy.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2021)
Review
Oncology
Lowell B. Anthony, Thomas M. O'Dorisio
Summary: Octreotide is commonly used for GEP-NETs and carcinoid syndrome, with two formulations available in the U.S. Challenges with the current depot-based treatment paradigm include unmet patient needs and bioactivity loss over time. Re-evaluating the role of immediate-release octreotide in combination with depot therapy may improve symptom control.
Article
Endocrinology & Metabolism
Marcus Quinkler, David Petroff, Ulrich J. Knappe, Jochen Schopohl, Anke Toenjes, Sebastian M. Schmid
Summary: In German patients with acromegaly, most patients receiving medical therapy have normal or low IGF-1 levels. The majority of patients are treated with somatostatin analogs, with some patients using a combination of different medical regimens. Some patients did not achieve normalization of IGF-1 levels.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
(2021)
Review
Biochemistry & Molecular Biology
Olesja Rogoza, Kaspars Megnis, Marija Kudrjavceva, Aija Gerina-Berzina, Vita Rovite
Summary: Somatostatin receptors play a crucial role in the treatment of neuroendocrine tumors, delaying tumor progression and regulating hormone overproduction. The expression level of SSTRs has predictive value in therapeutic response and patient survival rate. Future research will focus on other epigenetic regulators affecting somatostatin signaling and combination therapy strategies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Endocrinology & Metabolism
Leonidas Nikolaos Diamantopoulos, Faidon-Marios Laskaratos, Markos Kalligeros, Ruchir Shah, Shaunak Navalkissoor, Gopinath Gnanasegaran, Jamie Banks, Jack Smith, Benjamin Jacobs, Michail Galanopoulos, Dalvinder Mandair, Martyn Caplin, Christos Toumpanakis
Summary: In this study, above-label doses of somatostatin analogs showed promising antiproliferative effects in patients with inoperable/metastatic gastroenteropancreatic neuroendocrine tumors. Symptomatic improvement and disease control were observed in some patients after 3-weekly administration, with certain factors associated with inferior or better progression-free survival. Higher doses of SSAs may be beneficial as a bridge to other treatments, particularly for patients with specific tumor characteristics.
NEUROENDOCRINOLOGY
(2021)
Article
Endocrinology & Metabolism
Karina Zanlorenzi Basso Manosso, Carolina Labigalini Sampaio, Leandro Kasuki, Ximene Antunes, Monica R. Gadelha, Cesar Luiz Boguszewski
Summary: This study aimed to compare biochemical and tumor response rates between two reference centers for pituitary diseases in Brazil after primary and adjuvant therapy with somatostatin receptor ligands (SRL) in acromegaly. The results showed that there was no difference in the proportion of good responders in tumor shrinkage between the two centers when considering only IGF-I levels, but significant difference was found in the classification of full responders when both IGF-I and rGH levels were taken into account, with Center I showing a higher discrepancy.
Article
Endocrinology & Metabolism
E. Sala, G. Carosi, G. Del Sindaco, R. Mungari, A. Cremaschi, A. L. Serban, C. L. Ronchi, E. Ferrante, M. Arosio, G. Mantovani
Summary: A subset of well-controlled acromegalic patients can successfully withdraw from SAs, challenging the concept that medical therapy is a lifelong requirement.
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
(2021)
Article
Gastroenterology & Hepatology
Boukje T. Bootsma, Victor D. Plat, Tim van de Brug, Daitlin E. Huisman, M. Botti, Peter B. van den Boezem, Bert A. Bonsing, Koop Bosscha, Cornelis H. C. Dejong, Bas Groot-Koerkamp, Jeroen Hagendoorn, Erwin van der Harst, Ignace H. de Hingh, Vincent E. de Meijer, Misha D. Luyer, Vincent B. Nieuwenhuijs, Bobby K. Pranger, Hjalmar C. van Santvoort, Jan H. Wijsman, Barbara M. Zonderhuis, Geert Kazemier, Marc G. Besselink, Freek Daams
Summary: This study investigated the effect of different somatostatin analogues (SA) protocols on the incidence of postoperative pancreatic fistula (POPF) after pancreatoduodenectomy. The study found that the use of lanreotide in all patients undergoing pancreatoduodenectomy may have a protective effect on POPF development, and protocols for high-risk patients might be favorable as well. However, further studies are needed to confirm these findings.